STOP AF First Post-Approval Study

Inclusion Criteria:

• Subject has been diagnosed with symptomatic paroxysmal AF

• Subject is ≥ 18 years of age or minimum age as required by local regulations

• Planned pulmonary vein isolation (PVI) procedure using the commercially availableArctic Front™ cardiac cryoablation catheter System.

• Willing to comply with study requirements and give informed consent (defined aslegally effective, documented confirmation of a subject's voluntary agreement toparticipate in this clinical study) or authorization per institution andgeographical requirements

Exclusion Criteria:

History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1

. Subjects under the following conditions may be included in the study:

1. Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for aperiod of <4 weeks prior to the index PVI procedure)

2. Recent treatment with a class I or III AAD (within 6 months of the index PVIprocedure) at a dose below therapeutic threshold according to the AHA/ACC/HRSGuideline for the Management of Patients with Atrial Fibrillation

3. A subject who has received a chemical cardioversion may be included in the study.This includes a chemical cardioversion prior to enrollment and between enrollmentand ablation.

• Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)

• Subject is enrolled in a concurrent study that has not been approved forconcurrent enrollment by the global study manager

• Subject with exclusion criteria required by local law